Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $7.3 million.

  • Xeris Biopharma Holdings' Interest Expenses fell 641.03% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year decrease of 45.57%. This contributed to the annual value of $30.5 million for FY2024, which is 1462.29% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Interest Expenses of $7.3 million as of Q3 2025, which was down 641.03% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Interest Expenses peaked at $8.0 million during Q2 2024, and registered a low of $1.8 million during Q1 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Interest Expenses value was $6.5 million (recorded in 2023), while the average stood at $5.4 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Interest Expenses tumbled by 6086.96% in 2021 and then skyrocketed by 14261.11% in 2022.
  • Xeris Biopharma Holdings' Interest Expenses (Quarter) stood at $1.8 million in 2021, then soared by 142.61% to $4.4 million in 2022, then soared by 60.5% to $7.0 million in 2023, then rose by 9.86% to $7.7 million in 2024, then decreased by 5.19% to $7.3 million in 2025.
  • Its Interest Expenses was $7.3 million in Q3 2025, compared to $7.4 million in Q2 2025 and $7.3 million in Q1 2025.